General Information of Drug Off-Target (DOT) (ID: OT9T8WQM)

DOT Name Casein kinase II subunit alpha (CSNK2A1)
Synonyms CK II alpha; EC 2.7.11.1
Gene Name CSNK2A1
Related Disease
Okur-Chung neurodevelopmental syndrome ( )
Syndromic intellectual disability ( )
UniProt ID
CSK21_HUMAN
3D Structure
Download
2D Sequence (FASTA)
Download
3D Structure (PDB)
Download
PDB ID
1JWH ; 1NA7 ; 1PJK ; 2PVR ; 2ZJW ; 3AMY ; 3AT2 ; 3AT3 ; 3AT4 ; 3AXW ; 3BQC ; 3C13 ; 3FWQ ; 3H30 ; 3JUH ; 3MB6 ; 3MB7 ; 3NGA ; 3NSZ ; 3OWJ ; 3OWK ; 3OWL ; 3PE1 ; 3PE2 ; 3PE4 ; 3Q04 ; 3Q9W ; 3Q9X ; 3Q9Y ; 3Q9Z ; 3QA0 ; 3R0T ; 3RPS ; 3TAX ; 3U4U ; 3U87 ; 3U9C ; 3W8L ; 3WAR ; 3WIK ; 3WIL ; 3WOW ; 4DGL ; 4FBX ; 4GRB ; 4GUB ; 4GYW ; 4GYY ; 4GZ3 ; 4IB5 ; 4KWP ; 4MD7 ; 4MD8 ; 4MD9 ; 4NH1 ; 4RLL ; 4UB7 ; 4UBA ; 5B0X ; 5CLP ; 5CQU ; 5CQW ; 5CS6 ; 5CSH ; 5CSP ; 5CSV ; 5CT0 ; 5CTP ; 5CU0 ; 5CU2 ; 5CU3 ; 5CU4 ; 5CU6 ; 5CVF ; 5CVG ; 5CVH ; 5CX9 ; 5H8B ; 5H8E ; 5H8G ; 5HGV ; 5KU8 ; 5KWH ; 5M44 ; 5M4C ; 5M4F ; 5M4I ; 5MMF ; 5MMR ; 5MO5 ; 5MO6 ; 5MO7 ; 5MO8 ; 5MOD ; 5MOE ; 5MOH ; 5MOT ; 5MOV ; 5MOW ; 5MP8 ; 5MPJ ; 5N1V ; 5N9K ; 5N9L ; 5N9N ; 5NQC ; 5OMY ; 5ONI ; 5OQU ; 5ORH ; 5ORJ ; 5ORK ; 5OS7 ; 5OS8 ; 5OSL ; 5OSP ; 5OSR ; 5OSU ; 5OSZ ; 5OT5 ; 5OT6 ; 5OTD ; 5OTH ; 5OTI ; 5OTL ; 5OTO ; 5OTP ; 5OTQ ; 5OTR ; 5OTS ; 5OTY ; 5OTZ ; 5OUE ; 5OUL ; 5OUM ; 5OUU ; 5OWH ; 5OWL ; 5OYF ; 5T1H ; 5VIE ; 5VIF ; 5ZN0 ; 5ZN1 ; 5ZN2 ; 5ZN3 ; 5ZN4 ; 5ZN5 ; 6A1C ; 6E37 ; 6EHK ; 6EHU ; 6EII ; 6FVF ; 6FVG ; 6GIH ; 6GMD ; 6HBN ; 6HME ; 6HNW ; 6HNY ; 6HOP ; 6HOQ ; 6HOR ; 6HOT ; 6HOU ; 6JWA ; 6L1Z ; 6L21 ; 6L22 ; 6L23 ; 6L24 ; 6Q38 ; 6Q4Q ; 6QY7 ; 6RB1 ; 6RCB ; 6RCM ; 6RFE ; 6RFF ; 6SPW ; 6SPX ; 6TEI ; 6TLL ; 6TLO ; 6TLP ; 6TLR ; 6TLS ; 6TLU ; 6TLV ; 6TLW ; 6YPG ; 6YPH ; 6YPJ ; 6YPK ; 6YPN ; 6YUL ; 6YUM ; 6YZH ; 6Z19 ; 6Z83 ; 6Z84 ; 7A49 ; 7A4B ; 7A4C ; 7A4Q ; 7AT5 ; 7AY9 ; 7AYA ; 7B8H ; 7B8I ; 7BU4 ; 7L1X ; 7PSU ; 7QGB ; 7QGC ; 7QGD ; 7QGE ; 7QUX ; 7X4H ; 7Z39 ; 7ZWE ; 7ZWG ; 7ZY0 ; 7ZY2 ; 7ZY5 ; 7ZY8 ; 7ZYD ; 7ZYK ; 7ZYO ; 7ZYR ; 8AE7 ; 8AEC ; 8AEK ; 8AEM ; 8BGC ; 8P05 ; 8P07
EC Number
2.7.11.1
Pfam ID
PF00069
Sequence
MSGPVPSRARVYTDVNTHRPREYWDYESHVVEWGNQDDYQLVRKLGRGKYSEVFEAINIT
NNEKVVVKILKPVKKKKIKREIKILENLRGGPNIITLADIVKDPVSRTPALVFEHVNNTD
FKQLYQTLTDYDIRFYMYEILKALDYCHSMGIMHRDVKPHNVMIDHEHRKLRLIDWGLAE
FYHPGQEYNVRVASRYFKGPELLVDYQMYDYSLDMWSLGCMLASMIFRKEPFFHGHDNYD
QLVRIAKVLGTEDLYDYIDKYNIELDPRFNDILGRHSRKRWERFVHSENQHLVSPEALDF
LDKLLRYDHQSRLTAREAMEHPYFYTVVKDQARMGSSSMPGGSTPVSSANMMSGISSVPT
PSPLGPLAGSPVIAAANPLGMPVPAAAGAQQ
Function
Catalytic subunit of a constitutively active serine/threonine-protein kinase complex that phosphorylates a large number of substrates containing acidic residues C-terminal to the phosphorylated serine or threonine. Regulates numerous cellular processes, such as cell cycle progression, apoptosis and transcription, as well as viral infection. May act as a regulatory node which integrates and coordinates numerous signals leading to an appropriate cellular response. During mitosis, functions as a component of the p53/TP53-dependent spindle assembly checkpoint (SAC) that maintains cyclin-B-CDK1 activity and G2 arrest in response to spindle damage. Also required for p53/TP53-mediated apoptosis, phosphorylating 'Ser-392' of p53/TP53 following UV irradiation. Phosphorylates a number of DNA repair proteins in response to DNA damage, such as MDC1, RAD9A, RAD51 and HTATSF1, promoting their recruitment to DNA damage sites. Can also negatively regulate apoptosis. Phosphorylates the caspases CASP9 and CASP2 and the apoptotic regulator NOL3. Phosphorylation protects CASP9 from cleavage and activation by CASP8, and inhibits the dimerization of CASP2 and activation of CASP8. Phosphorylates YY1, protecting YY1 from cleavage by CASP7 during apoptosis. Regulates transcription by direct phosphorylation of RNA polymerases I, II, III and IV. Also phosphorylates and regulates numerous transcription factors including NF-kappa-B, STAT1, CREB1, IRF1, IRF2, ATF1, ATF4, SRF, MAX, JUN, FOS, MYC and MYB. Phosphorylates Hsp90 and its co-chaperones FKBP4 and CDC37, which is essential for chaperone function. Mediates sequential phosphorylation of FNIP1, promoting its gradual interaction with Hsp90, leading to activate both kinase and non-kinase client proteins of Hsp90. Regulates Wnt signaling by phosphorylating CTNNB1 and the transcription factor LEF1. Acts as an ectokinase that phosphorylates several extracellular proteins. During viral infection, phosphorylates various proteins involved in the viral life cycles of EBV, HSV, HBV, HCV, HIV, CMV and HPV. Phosphorylates PML at 'Ser-565' and primes it for ubiquitin-mediated degradation. Plays an important role in the circadian clock function by phosphorylating BMAL1 at 'Ser-90' which is pivotal for its interaction with CLOCK and which controls CLOCK nuclear entry. Phosphorylates CCAR2 at 'Thr-454' in gastric carcinoma tissue. Phosphorylates FMR1, promoting FMR1-dependent formation of a membraneless compartment.
Tissue Specificity Expressed in gastric carcinoma tissue and the expression gradually increases with the progression of the carcinoma (at protein level).
KEGG Pathway
Ribosome biogenesis in eukaryotes (hsa03008 )
NF-kappa B sig.ling pathway (hsa04064 )
Mitophagy - animal (hsa04137 )
Wnt sig.ling pathway (hsa04310 )
Adherens junction (hsa04520 )
Alzheimer disease (hsa05010 )
Prion disease (hsa05020 )
Pathways of neurodegeneration - multiple diseases (hsa05022 )
Measles (hsa05162 )
PD-L1 expression and PD-1 checkpoint pathway in cancer (hsa05235 )
Reactome Pathway
WNT mediated activation of DVL (R-HSA-201688 )
Condensation of Prometaphase Chromosomes (R-HSA-2514853 )
Signal transduction by L1 (R-HSA-445144 )
Regulation of TP53 Activity through Phosphorylation (R-HSA-6804756 )
Cooperation of PDCL (PhLP1) and TRiC/CCT in G-protein beta folding (R-HSA-6814122 )
Receptor Mediated Mitophagy (R-HSA-8934903 )
RUNX1 interacts with co-factors whose precise effect on RUNX1 targets is not known (R-HSA-8939243 )
Regulation of PTEN stability and activity (R-HSA-8948751 )
KEAP1-NFE2L2 pathway (R-HSA-9755511 )
Synthesis of PC (R-HSA-1483191 )

Molecular Interaction Atlas (MIA) of This DOT

2 Disease(s) Related to This DOT
Disease Name Disease ID Evidence Level Mode of Inheritance REF
Okur-Chung neurodevelopmental syndrome DISB295G Definitive Autosomal dominant [1]
Syndromic intellectual disability DISH7SDF Definitive Autosomal dominant [2]
------------------------------------------------------------------------------------
Molecular Interaction Atlas (MIA) Jump to Detail Molecular Interaction Atlas of This DOT
3 Drug(s) Affected the Post-Translational Modifications of This DOT
Drug Name Drug ID Highest Status Interaction REF
Valproate DMCFE9I Approved Valproate decreases the methylation of Casein kinase II subunit alpha (CSNK2A1). [3]
Capsaicin DMGMF6V Approved Capsaicin increases the phosphorylation of Casein kinase II subunit alpha (CSNK2A1). [15]
Benzo(a)pyrene DMN7J43 Phase 1 Benzo(a)pyrene increases the methylation of Casein kinase II subunit alpha (CSNK2A1). [17]
------------------------------------------------------------------------------------
20 Drug(s) Affected the Gene/Protein Processing of This DOT
Drug Name Drug ID Highest Status Interaction REF
Ciclosporin DMAZJFX Approved Ciclosporin increases the expression of Casein kinase II subunit alpha (CSNK2A1). [4]
Cupric Sulfate DMP0NFQ Approved Cupric Sulfate increases the expression of Casein kinase II subunit alpha (CSNK2A1). [5]
Estradiol DMUNTE3 Approved Estradiol increases the activity of Casein kinase II subunit alpha (CSNK2A1). [6]
Ivermectin DMDBX5F Approved Ivermectin decreases the expression of Casein kinase II subunit alpha (CSNK2A1). [7]
Arsenic DMTL2Y1 Approved Arsenic increases the expression of Casein kinase II subunit alpha (CSNK2A1). [8]
Quercetin DM3NC4M Approved Quercetin decreases the activity of Casein kinase II subunit alpha (CSNK2A1). [9]
Carbamazepine DMZOLBI Approved Carbamazepine affects the expression of Casein kinase II subunit alpha (CSNK2A1). [10]
Decitabine DMQL8XJ Approved Decitabine increases the expression of Casein kinase II subunit alpha (CSNK2A1). [11]
Selenium DM25CGV Approved Selenium decreases the expression of Casein kinase II subunit alpha (CSNK2A1). [12]
Aspirin DM672AH Approved Aspirin decreases the expression of Casein kinase II subunit alpha (CSNK2A1). [13]
Diclofenac DMPIHLS Approved Diclofenac affects the expression of Casein kinase II subunit alpha (CSNK2A1). [10]
Nicotine DMWX5CO Approved Nicotine increases the expression of Casein kinase II subunit alpha (CSNK2A1). [14]
Sulindac DM2QHZU Approved Sulindac decreases the expression of Casein kinase II subunit alpha (CSNK2A1). [13]
Tocopherol DMBIJZ6 Phase 2 Tocopherol decreases the expression of Casein kinase II subunit alpha (CSNK2A1). [12]
Geldanamycin DMS7TC5 Discontinued in Phase 2 Geldanamycin increases the expression of Casein kinase II subunit alpha (CSNK2A1). [18]
Bisphenol A DM2ZLD7 Investigative Bisphenol A increases the expression of Casein kinase II subunit alpha (CSNK2A1). [19]
Formaldehyde DM7Q6M0 Investigative Formaldehyde decreases the expression of Casein kinase II subunit alpha (CSNK2A1). [20]
3R14S-OCHRATOXIN A DM2KEW6 Investigative 3R14S-OCHRATOXIN A decreases the expression of Casein kinase II subunit alpha (CSNK2A1). [21]
QUERCITRIN DM1DH96 Investigative QUERCITRIN affects the expression of Casein kinase II subunit alpha (CSNK2A1). [22]
aconitine DMFOZ60 Investigative aconitine increases the expression of Casein kinase II subunit alpha (CSNK2A1). [23]
------------------------------------------------------------------------------------
⏷ Show the Full List of 20 Drug(s)
2 Drug(s) Affected the Protein Interaction/Cellular Processes of This DOT
Drug Name Drug ID Highest Status Interaction REF
Adenosine triphosphate DM79F6G Approved Adenosine triphosphate affects the binding of Casein kinase II subunit alpha (CSNK2A1). [16]
AMP-PNP DMTOK1D Investigative AMP-PNP affects the binding of Casein kinase II subunit alpha (CSNK2A1). [24]
------------------------------------------------------------------------------------

References

1 De novo mutations in CSNK2A1 are associated with neurodevelopmental abnormalities and dysmorphic features. Hum Genet. 2016 Jul;135(7):699-705. doi: 10.1007/s00439-016-1661-y. Epub 2016 Apr 5.
2 Technical standards for the interpretation and reporting of constitutional copy-number variants: a joint consensus recommendation of the American College of Medical Genetics and Genomics (ACMG) and the Clinical Genome Resource (ClinGen). Genet Med. 2020 Feb;22(2):245-257. doi: 10.1038/s41436-019-0686-8. Epub 2019 Nov 6.
3 Integrative omics data analyses of repeated dose toxicity of valproic acid in vitro reveal new mechanisms of steatosis induction. Toxicology. 2018 Jan 15;393:160-170.
4 Comparison of HepG2 and HepaRG by whole-genome gene expression analysis for the purpose of chemical hazard identification. Toxicol Sci. 2010 May;115(1):66-79.
5 Physiological and toxicological transcriptome changes in HepG2 cells exposed to copper. Physiol Genomics. 2009 Aug 7;38(3):386-401.
6 Estrogen regulates epithelial cell deformability by modulation of cortical actomyosin through phosphorylation of nonmuscle myosin heavy-chain II-B filaments. Endocrinology. 2006 Nov;147(11):5236-48. doi: 10.1210/en.2006-0779. Epub 2006 Aug 10.
7 Quantitative proteomics reveals a broad-spectrum antiviral property of ivermectin, benefiting for COVID-19 treatment. J Cell Physiol. 2021 Apr;236(4):2959-2975. doi: 10.1002/jcp.30055. Epub 2020 Sep 22.
8 Genome-wide analysis of BEAS-2B cells exposed to trivalent arsenicals and dimethylthioarsinic acid. Toxicology. 2010 Jan 31;268(1-2):31-9.
9 Alternaria toxins as casein kinase 2 inhibitors and possible consequences for estrogenicity: a hybrid in silico/in vitro study. Arch Toxicol. 2020 Jun;94(6):2225-2237. doi: 10.1007/s00204-020-02746-x. Epub 2020 Apr 23.
10 Drug-induced endoplasmic reticulum and oxidative stress responses independently sensitize toward TNF-mediated hepatotoxicity. Toxicol Sci. 2014 Jul;140(1):144-59. doi: 10.1093/toxsci/kfu072. Epub 2014 Apr 20.
11 Silencing of the CKII alpha and CKII alpha' genes during cellular senescence is mediated by DNA methylation. Gene. 2009 Feb 15;431(1-2):55-60. doi: 10.1016/j.gene.2008.10.020. Epub 2008 Nov 6.
12 Selenium and vitamin E: cell type- and intervention-specific tissue effects in prostate cancer. J Natl Cancer Inst. 2009 Mar 4;101(5):306-20.
13 Expression profile analysis of colon cancer cells in response to sulindac or aspirin. Biochem Biophys Res Commun. 2002 Mar 29;292(2):498-512.
14 Downregulation of Stem-Loop Binding Protein by Nicotine via 7-Nicotinic Acetylcholine Receptor and Its Role in Nicotine-Induced Cell Transformation. Toxicol Sci. 2022 Sep 24;189(2):186-202. doi: 10.1093/toxsci/kfac080.
15 Capsaicin, a component of red peppers, stimulates protein kinase CKII activity. BMB Rep. 2010 May;43(5):325-9. doi: 10.5483/bmbrep.2010.43.5.325.
16 Discovery and SAR of 5-(3-chlorophenylamino)benzo[c][2,6]naphthyridine-8-carboxylic acid (CX-4945), the first clinical stage inhibitor of protein kinase CK2 for the treatment of cancer. J Med Chem. 2011 Jan 27;54(2):635-54.
17 Air pollution and DNA methylation alterations in lung cancer: A systematic and comparative study. Oncotarget. 2017 Jan 3;8(1):1369-1391. doi: 10.18632/oncotarget.13622.
18 Identification of transcriptome signatures and biomarkers specific for potential developmental toxicants inhibiting human neural crest cell migration. Arch Toxicol. 2016 Jan;90(1):159-80.
19 Modelling cardiac fibrosis using three-dimensional cardiac microtissues derived from human embryonic stem cells. J Biol Eng. 2019 Feb 13;13:15. doi: 10.1186/s13036-019-0139-6. eCollection 2019.
20 Characterization of formaldehyde's genotoxic mode of action by gene expression analysis in TK6 cells. Arch Toxicol. 2013 Nov;87(11):1999-2012.
21 Persistence of epigenomic effects after recovery from repeated treatment with two nephrocarcinogens. Front Genet. 2018 Dec 3;9:558.
22 Molecular mechanisms of quercitrin-induced apoptosis in non-small cell lung cancer. Arch Med Res. 2014 Aug;45(6):445-54.
23 Notch1-mediated histone demethylation of HCN4 contributes to aconitine-induced ventricular myocardial dysrhythmia. Toxicol Lett. 2020 Jul 1;327:19-31. doi: 10.1016/j.toxlet.2020.03.017. Epub 2020 Mar 28.
24 Simultaneous CK2/TNIK/DYRK1 inhibition by 108600 suppresses triple negative breast cancer stem cells and chemotherapy-resistant disease. Nat Commun. 2021 Aug 3;12(1):4671. doi: 10.1038/s41467-021-24878-z.